Drug intelligence / Profile preview

LB-200

Development stage: Discontinued
Lead developer: Lixte Biotechnology Holdings
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous, Intravenous

Overview

LB-200 is a compound being developed by Lixte Biotechnology as part of its LB-100 and LB-200 series for cancer treatment. Research on this series, including LB-200, was conducted under a Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurologic Disorders and Stroke (NINDS) from 2006 to 2013. The compounds were evaluated for their ability to inhibit brain tumor cell growth, with an initial focus on glioblastoma multiforme, and later expanding to other cancers such as medulloblastoma and neuroblastoma.

Beyond the preview

Go deeper on LB-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LB-200.

Explore the full profile